Skip to content
Study details
Enrolling now

Psilocybin rTMS for Treatment Resistant Depression

University of Texas at Austin
NCT IDNCT06132178ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

100

Study length

about 6 years

Ages

22–65

Locations

1 site in TX

What this study is about

This trial is testing whether giving psilocybin after a short, brain stimulation treatment (aiTBS) can help people with depression that hasn't responded to other treatments. The goal is to see if this combination is safe and works.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Low-dose psilocybin
  • 2.Take Psilocybin
  • 3.Use Accelerated intermittent theta burst (aiTBS) rTMS treatment
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug routes

oral

Endpoints

Primary: Montgomery Asberg Depression Rating Scale (MADRS)

Secondary: Beck Depression Inventory II (BDI II), Columbia-Suicide Severity Rating Scale (C-SSRS), Discontinuation Emergent Signs and Symptoms Scale, Generalized Anxiety Disorder 7 (GAD-7), Mood and Anxiety Symptom Questionnaire 30 item Anhedonic Depression subscale (MASQ-30), Mood and Anxiety Symptom Questionnaire 30 item Anxious Arousal subscale (MASQ-30), Physicians Health Questionnaire 9 (PHQ-9), Quick Inventory of Depressive Symptom Self-Report (QIDS-SR)

Devices

therapeutic

Body systems

Psychiatry / Mental Health